|Bid||5.93 x 1200|
|Ask||11.63 x 1100|
|Day's Range||5.97 - 6.01|
|52 Week Range||4.85 - 11.55|
|Beta (3Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all...
Chembio (CEMI) reported financial results for their fourth quarter ending December 31st and provided an operating update. Product sales were just about dead-on with our estimate and up 16% yoy to $5.6M. Total revenue jumped 27% to $7.6M, aided by a very healthy $1.7M in R&D contracts, milestones and grant revenue – which is the greatest quarterly revenue from this category in company history.
Chembio Diagnostics Inc develops, manufactures, and commercializes point of care diagnostic tests that detect infectious diseases. Warning! GuruFocus has detected 4 Warning Signs with CEMI. For the last quarter Chembio Diagnostics Inc reported a revenue of $7.60 million, compared with the revenue of $5.99 million during the same period a year ago.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales haveRead More...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...
Chembio Diagnostics, Inc.'s (NASDAQ:CEMI): Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. With the latest Read More...
Chembio (CEMI) reported financial results for their third quarter ending September 30, 2018. Q3 made it three-for-three with us substantially underestimating product and total revenue every quarter so far in 2018. While it is unclear exactly what is catalyzing product revenue or where we’re missing, recently secured contracts (such as that with Bio-Manghinos) and international tenders (including the $15.8M tender from Ethiopia) are undoubtedly significant contributors to the record YTD revenue.
When a Zika epidemic was at its height in the Americas two years ago, diagnostics makers began working feverishly to create diagnostic tests for a virus that few in the U.S. had heard of. A lack of testing capacity has hampered efforts to track Zika in Angola, where a largely unreported cluster of microcephaly cases has been linked to the virus, and left mothers vulnerable to an illness that can cause severe birth defects in developing fetuses. WHY IS IT SO HARD TO TEST FOR ZIKA?
If you are currently a shareholder in Chembio Diagnostics Inc (NASDAQ:CEMI), or considering investing in the stock, you need to examine how the business generates cash, and how it isRead More...
Q2 2018: Ethiopian Tender, Bio-Manguinhos Order Propel Product Sales. Product sales remain very strong, up 137% yoy and +7% from Q1 and bolstered by both of these recent contract wins (i.e. Both the DPP Zika and Chikungunya tests have received ANVISA approval.